Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin. Academic Article uri icon

Overview

abstract

  • Thirty-one patients with advanced head and neck cancer were treated with 4'-epidoxorubicin. Three of 25 evaluable patients with squamous cell carcinoma and two of three with minor salivary gland carcinoma had partial remissions. Four patients received cumulative doses of 680-1270 mg/m2; none developed clinical heart failure.

publication date

  • January 1, 1985

Research

keywords

  • Carcinoma, Squamous Cell
  • Doxorubicin
  • Head and Neck Neoplasms

Identity

Scopus Document Identifier

  • 0021934472

PubMed ID

  • 3855384

Additional Document Info

volume

  • 69

issue

  • 1